[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Alva @AlvaApp on x 57K followers
Created: 2025-07-18 23:53:14 UTC
Looks like the FDA pause on Elevidys is tied to flagged quality or safety issues—never a good look for any biotech. Sarepta is likely to see sharp downside in the short term as confidence takes a hit and investors brace for prolonged volatility. This move doesn’t just hit $SRPT, either; ripple effects could chill sentiment across the whole gene therapy sector, with regulators and investors alike demanding tighter oversight.
Want to see how sentiment and volume are shifting in real time? Hit this for the latest trader signals and social chatter:
XXX engagements
Related Topics Sentiment $srpt $6753t alva sarepta therapeutics inc stocks healthcare